Advanced search
Publication Cover
Leukemia & Lymphoma Volume 40, 2001 - Issue 3-4
Submit an article Journal homepage
24
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Bleomycin, Lomustine, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BLEO-CCVPP) in Patients with Hodgkin's Disease who Relapsed after Radiotherapy Alone: a Long-Term Foliow-Up Study of the Eastern Cooperative Oncology Group (E3481)

Peter H. Wiernik OLM Comprehensive Cancer Center, New York Medical College, Bronx, New YorkCorrespondence[email protected]
,
Traci Leong Dana Farber Cancer Institute, Boston Massachusetts, Minneapolis, Minnesota
,
Martin M. Oken Virginia Piper Cancer Institute, Minneapolis, Minnesota
,
Richard S. Neiman Indiana University Medical Center, Indianapolis, Indiana
,
Thomas M. Habermann Mayo Clinic, Rochester, Minnesota
,
John M. Bennett University of Rochester Cancer Center, Rochester, New York
,
Stephen Schuster University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
&
John H. Glick University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
 show all
Pages 357-363 | Received 20 Feb 2000, Published online: 01 Jul 2009

References

  • Strauss D. J. Treatment of early stage Hodgkin's disease. Blood Reviews 1993; 7: 34–42
  • Yahalom J. Re-Visiting the role of radiation therapy in Hodgkin's disease. Isr J Med Sci 1995; 31: 137–143
  • Bergsagel D. E. Salvage treatment for Hodgkin's disease in relapse. J Clin Oncol 1987; 5: 525–526
  • Appelfeld M. M., Wiemik P. H. Cardiac disease after radiation therapy for Hodgkin's disease: Analysis of 48 patients. Am J Cardiol 1983; 51: 1679–1681
  • Hancock S. L., Tucker M. A., Hoppe R. T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. J Am Med Assn 1993; 270: 1949–1955
  • Oken M. M., Creech R. H., Tormey D. C. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655
  • O'Connell M. J., Harrington D. P., Earle J. D., Johnson G. J., Glick J. H., Neiman R. S., Silverstein M. N. Chemotherapy follwoed by consolidation radiaotherapy for the treatment of clinical stage II aggressive histologic type non-Hodgkin's lymphoma. Cancer 1988; 61: 1754–1758
  • Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J Am Statis Assn 1958; 53: 457–481
  • Jones S. E., Haut A., Weick J. K., Wilson H. E., Grozea P., Fabian C. J., McKelvey E., Byrne G. E., Hartsock R., Dixon D. O., Coltman C. A., Jr. Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-bleomycin in the management of advanced Hodgkin's disease. Cancer 1983; 51: 1339–1347
  • Nissen N. I., Pajak T. F., Glidewell O., Pedersen-Bjergaard J., Stutzman L., Falkson G., Cuttner J., Blom J., Leone L., Sawitsky A., Coleman M., Haurani R., Spurr C. L., Harley J. B., Seligman B., Cornell C., Jr, Henry P., Senn H. J., Brunner K., Martz G., Maurice P., Bank A., Shapiro L., James G. W., Holland J. F. A comparative study of BCNU containing 4-drug program versus MOPP versus 3-drug combination in advanced Hodgkin's disease. Cancer 1979; 43: 31–40
  • Simmonds P. D., Mead G. M., Sweetenham J. W., O'Callaghan A., Smartt P., Kerr J., Hamilton C. R., Golding P. F., Milne A. E., Whitehouse J. M. A. PACE BOM chemotherapy: A 12-week regimen for advanced Hodgkin's disease. Ann Oncol 1997; 8: 259–266
  • van Rijswijk R. E., Haanen C., Dekker A. W., de Meijer A. J., Verbeek J. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 1989; 7: 1776–1782
  • Diggs C. H., Wiemik P. H., Levi J. A., Kvols L. K. Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease. Cancer 1977; 39: 1949–1954
  • Vinciguerra V., Propert K. J., Coleman M., Anderson J. R., Stutzman L., Pajak T. F., Nissen N. I., Frizzera G., Gottlieb A., Holland J. F. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy: A prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol 1986; 4: 838–846
  • Canellos G. P., Anderson J. R., Propert K. J., Nissen N., Cooper M. R., Henderson E. S., Green M. R., Gottlieb A., Peterson B. A. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484
  • Wiernik P. H., Dutcher J. P., Einzig A. I., Sparano J., Frank M. Mitoxantrone, vinblastine and lomustine (CCNU) (MVC): A highly active regimen for advanced and poor-prognosis Hodgkin's disease. Cancer J Sci Am 1998; 4: 254–260
  • Colwill R., Crump M., Couture F., Danish R., Stewart A. K., Sutton D. M. C., Scott J. G., Sutcliffe S. B., Brandwein J. M., Keating A. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995; 13: 396–402
  • Reece D. E., Barnett M. J., Shepherd J. D., Hogge D. E., Klassa R. J., Nantel S. H., Sutherland H. J., Klingemann H. G., Fairey R. N., Voss N. J., Connors J. M., O'Reilly S. E., Spinelli J. J., Phillips G. L. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16–213) with or without cisplatin (CBV+/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86: 451–456
  • Mauch P. M., Kalish L. A., Marcus K. C., Coleman C. N., Shulman L. N., Krill E., Come S., Silver B., Canellos G. P., Tarbell N. J. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 1996; 87: 3625–3632

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.